Cardinal Health 105, Inc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Cardinal Health 105, Inc Pharmaceutical Import Records from India — 2 Products, $600.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Cardinal Health 105, Inc — Pharmaceutical Importer Profile (2026) | 2 Products, $600.0K Trade | TransData Nexus

Cardinal Health 105, Inc

Pharmaceutical Importer · United States · Analgesics & Antipyretics Focus · $600.0K Total Trade · DGFT Verified

Cardinal Health 105, Inc is a pharmaceutical importer based in United States with a total trade value of $600.0K across 2 products in 2 therapeutic categories. Based on 12 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Cardinal Health 105, Inc sources from 1 verified Indian supplier, with Gland Pharma Limited accounting for 100.0% of imports.

Cardinal Health 105, Inc — Import Portfolio & Supplier Network

Cardinal Health 105, Inc import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Cardinal Health 105, Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Gland Pharma Limited	$432.6K	10	100.0%

Cardinal Health 105, Inc sources from 1 verified Indian supplier across 3 distinct formulations. The sourcing is highly concentrated — Gland Pharma Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Cardinal Health 105, Inc Import?

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Ketorolac	Analgesics & Antipyretics	$350.0K	7	0.3%	14
2	Ertapenem	Advanced Antibiotics	$250.0K	5	0.2%	19

Cardinal Health 105, Inc imports 2 pharmaceutical products across 2 categories into United States totaling $600.0K.

Cardinal Health 105, Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Cardinal Health 105, Inc. is a subsidiary of Cardinal Health, Inc., a leading American multinational healthcare services and products company headquartered in Dublin, Ohio. Established in 1971, Cardinal Health specializes in the distribution of pharmaceuticals and medical products, serving over 100,000 locations worldwide. The company operates in two primary segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. Cardinal Health 105, Inc. functions as a pharmaceutical importer and buyer, focusing on sourcing finished pharmaceutical formulations from international markets, including India, to meet the diverse needs of the U.S. healthcare system.

As a key player in the U.S. pharmaceutical distribution network, Cardinal Health 105, Inc. plays a crucial role in ensuring the availability of a wide range of pharmaceutical products. By importing finished formulations, the company contributes to the efficiency and effectiveness of the U.S. healthcare supply chain, facilitating access to essential medications for hospitals, pharmacies, and other healthcare providers. This strategic approach enables Cardinal Health 105, Inc. to address market demands and support the delivery of quality healthcare services across the nation.

2Distribution Network

Cardinal Health 105, Inc. leverages Cardinal Health's extensive distribution network to facilitate the importation and distribution of pharmaceutical products. While specific warehouse locations for Cardinal Health 105, Inc. are not publicly disclosed, Cardinal Health operates numerous distribution centers across the United States, strategically positioned to ensure efficient logistics and timely delivery of products. This widespread infrastructure enables the company to serve a vast geographic area, encompassing both urban and rural regions, thereby meeting the diverse needs of the U.S. healthcare system.

The company's logistics capabilities are designed to handle a broad spectrum of pharmaceutical products, including temperature-sensitive items, ensuring compliance with regulatory standards and maintaining product integrity throughout the supply chain. By utilizing Cardinal Health's established distribution network, Cardinal Health 105, Inc. can effectively manage the complexities associated with pharmaceutical importation, including customs clearance, regulatory compliance, and inventory management, thereby supporting the seamless delivery of medications to healthcare providers nationwide.

3Industry Role

Cardinal Health 105, Inc. operates as a pharmaceutical importer and buyer within the U.S. healthcare supply chain. By sourcing finished pharmaceutical formulations from international markets, including India, the company supplements the domestic supply of medications, ensuring a diverse and reliable product offering for healthcare providers. This role is particularly significant in addressing market demands for specific drugs, managing supply shortages, and providing cost-effective alternatives to domestically produced pharmaceuticals.

In the broader context of the U.S. pharmaceutical industry, Cardinal Health 105, Inc. contributes to the resilience and flexibility of the supply chain. By engaging in international sourcing, the company helps mitigate risks associated with domestic production limitations, such as manufacturing disruptions or capacity constraints. This strategic approach enhances the overall stability of the pharmaceutical supply chain, ensuring that healthcare providers have access to a continuous and diverse supply of essential medications.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Cardinal Health 105, Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Cardinal Health 105, Inc. demonstrates a high degree of sourcing concentration, importing finished pharmaceutical formulations exclusively from a single supplier, GLAND PHARMA LIMITED, which accounts for 100% of its pharmaceutical imports from India. This singular sourcing strategy indicates a strong, possibly strategic, partnership between Cardinal Health 105, Inc. and GLAND PHARMA LIMITED, facilitating streamlined procurement processes and potentially favorable terms.

However, this concentrated sourcing approach also introduces certain risks. Dependence on a single supplier can lead to vulnerabilities in the event of supply chain disruptions, such as manufacturing issues, regulatory challenges, or geopolitical events affecting the supplier's operations. The shipment data, comprising 12 shipments valued at $600K USD over the period from 2022 to 2026, suggests a consistent and stable relationship between the two entities. Nonetheless, the lack of diversification in the supplier base may limit Cardinal Health 105, Inc.'s ability to adapt to changing market conditions or to leverage competitive pricing from multiple sources.

2Supply Chain Resilience

The resilience of Cardinal Health 105, Inc.'s supply chain is closely tied to the stability and reliability of its sole supplier, GLAND PHARMA LIMITED. With all pharmaceutical imports originating from this single source, the company's supply chain is highly susceptible to any disruptions affecting GLAND PHARMA LIMITED's operations. Factors such as manufacturing delays, quality control issues, or regulatory challenges faced by the supplier could directly impact Cardinal Health 105, Inc.'s ability to meet the pharmaceutical needs of its U.S. clientele.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation of pharmaceutical products. The FDA's mission is to protect public health by ensuring that drugs imported into the U.S. meet standards for quality, safety, and effectiveness. This includes reviewing shipments of imported drugs to determine their admissibility and conducting inspections to verify compliance with applicable laws and regulations.

Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act (FD&C Act), which outlines the requirements for drug safety and efficacy. Under this act, drugs must be proven to be safe and effective before they can be sold in the U.S. Additionally, the FDA's Regulatory Procedures Manual provides detailed guidelines on import operations and actions, ensuring that imported drugs comply with U.S. standards.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are stringent. All foreign drug establishments whose products are imported must register with the FDA and list all their drug products intended for commercial distribution in the U.S. This registration process ensures that the FDA is notified of all regulated products imported into the country.

Cardinal Health 105, Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Cardinal Health 105, Inc.'s focus on importing finished pharmaceutical formulations in the therapeutic categories of Analgesics & Antipyretics and Advanced Antibiotics aligns with market demand for pain management and infection control. The substantial import values of Ketorolac ($350K) and Ertapenem

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Cardinal Health 105, Inc

What products does Cardinal Health 105, Inc import from India?

Cardinal Health 105, Inc imports 2 pharmaceutical products across 2 categories. Top imports: Ketorolac ($350.0K), Ertapenem ($250.0K).

Who supplies pharmaceuticals to Cardinal Health 105, Inc from India?

Cardinal Health 105, Inc sources from 1 verified Indian suppliers. The primary supplier is Gland Pharma Limited (100.0% of imports, $432.6K).

What is Cardinal Health 105, Inc's total pharmaceutical import value?

Cardinal Health 105, Inc's total pharmaceutical import value from India is $600.0K, based on 12 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Cardinal Health 105, Inc focus on?

Cardinal Health 105, Inc imports across 2 categories. The largest: Analgesics & Antipyretics (58.3%), Advanced Antibiotics (41.7%).

Get Full Cardinal Health 105, Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.

Formulation	Value	Ships
Ketorolac tromethamine injection USP	$332.9K	7
Labetalol hcl injection USP 200MG/40ML	$51.8K	2
Ondansetron injection 4MG/2ML (2MG/ML)	$47.9K	1